<DOC>
	<DOC>NCT00189761</DOC>
	<brief_summary>A study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (MR4) in de novo bone marrow transplant recipients</brief_summary>
	<brief_title>A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Bone marrow transplantation patients aged 2054 except for transplanted from genetically HLA matched sibling donor. The patient had been fully informed. The patient had severe impaired hepatic function. The patient had impaired renal function. The patient had existing complication of severe cardiac dysfunction. The patient had severe impaired pulmonary function.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Graft versus Host Disease</keyword>
</DOC>